Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of V-01 recombinant SARS-CoV-2 fusion protein vaccine in adults
PACTR202107562417077Phase 3Not yet recruiting
- Sponsor
- Livzon Monoclonal Antibody
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of V-01 in coronavirus disease 2019 (COVID-19), sponsored by Livzon Monoclonal Antibody. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
V-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202107562417077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202107562417077.